-
Eur. J. Paediatr. Neurol. · Mar 2016
Clinical experience of intravenous lacosamide in infants and young children.
- Dimitrios Arkilo, Mary Gustafson, and Frank J Ritter.
- Minnesota Epilepsy Group, P.A.(®) of United Hospital and Children's Hospitals and Clinics of Minnesota, 225 Smith Ave N, # 201, St. Paul, MN 55102, USA; Children's Hospital and Clinics of Minnesota, 225 Smith Ave N, #201, St. Paul, Minnesota, USA. Electronic address: arkdimi@hotmail.com.
- Eur. J. Paediatr. Neurol. 2016 Mar 1; 20 (2): 212-217.
ObjectiveTo review our clinical experience with intravenous (iv) lacosamide (LCM) in children less than 12 years old.BackgroundUse of LCM to treat children with epilepsy has been supported by multiple studies with limited information on iv use in children.Designs/MethodsAll children given iv LCM were identified from 2009 to 2015. Records were audited for demographics, seizure classification, etiology, EEG, imaging, indication. Baseline seizure frequency was based on parental reporting, continuous video EEG and direct observation.Results47 patients were identified with median age 6.5 years, 18 less than 3 years old, including 8 younger than 12 months. LCM was an adjunctive therapy of ≥2 antiepileptic drugs (AEDs). LCM was administered intravenously to treat epilepsia partialis continua (n = 3, dose range 5-10 mg/kg), status epilepticus (n = 11, median dose 7.2 mg/kg, range 4-11 mg/kg), and acute exacerbation of seizure frequency (n = 18, median dose 4.5 mg/kg, range 1-11 mg/kg). Parenteral form was substituted for oral form for 10 children treated with maintenance LCM unable to ingest/tolerate enteral medication and 5 who were given iv LCM to initiate maintenance treatment (median dose 4 mg/kg, range: 2-10 mg/kg). The infusion was effective for 24 out of 37 children (65%) naive to LCM. Sedation (one with ataxia) was noted in 5/36 children (14%), without any other identified adverse events.ConclusionThis is the first published retrospective study of very young critically ill children receiving iv LCM. The acute tolerability at this dosing range represents a positive trend and need confirmation from larger studies.Copyright © 2016 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.